Response of multicentric desmoid tumours to tamoxifen

Procter, H. A.; Singh, Latavia; Baum, Michael; Brinkley, Diana

doi:10.1002/bjs.1800740527

Cited by 63 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 Antagonistic effects on both platelet-derived growth factor-␤ (PDGF-␤) production and prostaglandin metabolism also may contribute to the efficacy of this drug. 31,[33][34][35][36][37] Conventional cytotoxic therapy also has demonstrated anecdotal success, occasionally producing prolonged progression-free periods. 11,26,35,38 -44 In our experience, prolonged treatment confers a proportionally longer progression-free period; however, toxicity limits the duration and success of this approach.…”

Section: Results Both Patients Demonstrated Ongoing Radiographic Andmentioning

confidence: 99%

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

Mace

Biermann

Sondak

et al. 2002

Cancer

182

110

View full text Add to dashboard Cite

BACKGROUNDDesmoid tumor represents a rare monoclonal neoplasm arising from deep musculoaponeurotic structures and may occur sporadically or in association with the familial adenomatous polyposis and Gardner syndromes. Desmoid tumors do not appear to demonstrate metastatic potential; however, local infiltrative growth results in significant morbidity and potential mortality. Although the delineation of optimal therapy for desmoid tumors has been confounded by several factors, surgical resection with adjuvant radiotherapy for a positive surgical margin remains the standard approach. Responses have been demonstrated to nonsteroidal antiinflammatory agents, antiestrogen compounds, and a variety of other agents in small series. Imatinib mesylate appears to demonstrate inhibitory activity against multiple class 3 receptor tyrosine kinases, including platelet‐derived growth factor receptor (PDGFR)‐α and PDGFR‐β, as well as c‐kit.METHODSThe authors performed immunohistochemical and qualitative real‐time polymerase chain reaction analysis on nine desmoid tumor specimens that demonstrated consistent positivity for c‐kit as well as PDGFR‐α and PDGFR‐β. At the time of last follow‐up, 2 patients had received therapy with imatinib mesylate at a dose of 400 mg twice daily.RESULTSBoth patients demonstrated ongoing radiographic and clinical responses with a duration of 9 months and 11 months, respectively.CONCLUSIONSImatinib mesylate has been reported to have activity against desmoid tumor, most likely because of c‐kit and PDGFR receptor tyrosine kinase activity inhibition, and warrants further study. The relative novelty of this agent and the lack of long‐term toxicity data should prompt its use only in the salvage setting in which established local and systemic approaches fail to control disease. In addition, the use of imatinib mesylate in the treatment of this neoplasm preferably should be in the context of a formal prospective clinical trial. Cancer 2002;95:2373–9. © 2002 American Cancer Society.DOI 10.1002/cncr.11029

show abstract

Section: Results Both Patients Demonstrated Ongoing Radiographic Andmentioning

confidence: 99%

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

Mace

Biermann

Sondak

et al. 2002

Cancer

182

110

View full text Add to dashboard Cite

show abstract

“…Finally, some authors have also reported objective responses following endocrine manipulations with antiestrogen [23,25,30,36,38,41,43,55,63], antiprostaglandin [55], and nonsteroidal anti-inflammatory drugs [24,26,45,49,55]. Other authors, however, reported treatment failures [5,22,26,39,63].…”

Section: Discussionmentioning

confidence: 89%

Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin

et al. 2000

View full text Add to dashboard Cite

“…Desmoi de wur den ex pe ri men tell durch Östro-gen appli ka tio nen in du ziert [28,48]. Anti östro ge ne wie Ta mo xi fen üben einen wachs tums hem men den Ef fekt aus [8,16,28,30,43,48]. Östro gen re zep to ren wur den in 36, An ti östro gen re zep to ren in 79 aller Des moi de ge fun den [20,29,42,45].…”

Section: äTio Lo Gieunclassified

Extraabdominelle Fibromatose

Ernst¹,

Todt²,

Seidl

2005

HNO

View full text Add to dashboard Cite

Musculoaponeurotic fibromatosis or desmoid tumors are rare. We report the case of a 57 year old woman with a slowly growing tumor behind the sternocleidomastoid muscle, which was completely removed. Histological examination confirmed the clinical suspicion of a desmoid tumor. Desmoid tumors are aggressive, locally infiltrating, non-metastasizing tumors with a high local recurrence. Genetic, endocrine and physical factors have been implicated as causative agents. The diagnosis is made histologically, reactive fibromatosis and fibrosarcoma must be eliminated in differential diagnosis. By the combination of different radiographic techniques, it is possible to describe the tumors and differentiate between vessels, nerves and bones. The therapy of the choice is the surgical resection. Adjuvant therapy, such as x-ray treatment, chemo- and hormone therapy, are indicated when the tumor is inoperable or too extensive for surgery.

show abstract

Response of multicentric desmoid tumours to tamoxifen

Cited by 63 publications

References 9 publications

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin

Extraabdominelle Fibromatose

Contact Info

Product

Resources

About